An­ti­sense start­up Stoke Ther­a­peu­tics se­cures an­oth­er $90M in se­ries B fund­ing

Led by for­mer Sarep­ta CEO, an­ti­sense start­up Stoke Ther­a­peu­tics has raked in $90 mil­lion in se­ries B fi­nanc­ing, fol­low­ing up the $40 mil­lion an­nounced ear­li­er this year.

Stoke li­censed its tech­nol­o­gy, the so-called Tar­get­ed Aug­men­ta­tion of Nu­clear Gene Out­put (TAN­GO), from Cold Spring Har­bor Lab­o­ra­to­ry’s Adri­an Krain­er, who is cred­it­ed as the in­ven­tor of Bio­gen’s $BI­IB spinal mus­cu­lar at­ro­phy drug Spin­raza. The $90 mil­lion in fund­ing comes from RTW In­vest­ments with par­tic­i­pa­tion from found­ing in­vestor Ap­ple Tree Part­ners, that sup­plied the orig­i­nal $40 mil­lion in­jec­tion in Jan­u­ary.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.